| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 7909.6 | 8017.0 | 6123.2 |
| Other income | 129.9 | 106.1 | 109.0 |
| Total income | 8039.5 | 8123.1 | 6232.2 |
| Profit before exceptional items & tax | 1260.4 | 1387.3 | 1728.4 |
| Exceptional items | 1.3 | -18.2 | -34.2 |
| Profit before tax | 1261.7 | 1369.1 | 1694.2 |
| Net profit | 925.5 | 960.4 | 1260.9 |
| Operating margin | 15.7% | 16.9% | 27.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -26.60% |
|---|---|
| Net profit, quarter on quarter | -3.60% |
| Revenue, year on year | +29.20% |
| Operating profit, year on year | -30.20% |
| Operating profit, quarter on quarter | -11.80% |
NSE results filing, NSE: ZYDUSLIFE. Figures extracted from the filing.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,199.70
- Market cap
- ₹1,20,718 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 41.3×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Results Update
Zydus Lifesciences reported Q2 FY27 revenue of Rs. 79,096 mn, up 29% y-o-y. H1 net profit was Rs. 18,859 mn, down 31%.
Zydus Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 7,910 Cr (+29% YoY), EBITDA Rs 1,895 Cr at 24.0% margin, reported PAT Rs 926 Cr (-26.6% YoY). Branded India and North America drove growth; FX and D&A weighed on profit.
Zydus Lifesciences Other Announcement
Zydus Lifesciences board approved appointment of Walker Chandiok & Co LLP as statutory auditors for a five-year term. This follows mandatory rotation of outgoing auditor Deloitte Haskins and Sells LLP.
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr
Zydus Lifesciences Acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.